Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Monthly Archives: February 2012
Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease
Posted: Published on February 28th, 2012
NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients. In the preclinical studies conducted by leading scientists including Professors Melamed and Offen of Tel Aviv University and originally reported in Experimental Neurology, patients' bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) that were transplanted into an animal model of Huntington disease showed therapeutic benefits. Addressing the role of these MSC-NTF cells in Huntington disease, Professor Daniel Offen explains, "the premise is that such cells can be transplanted safely into affected areas of the brain, and thereby serve as vehicles for delivering neurotrophic factors." Offen expressed his hope that this cell-based therapy may eventually progress to the clinic. BrainStorm is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results have shown that Brainstorm’s NurOwn™ therapy is safe, does not show any significant treatment-related … Continue reading
Comments Off on Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease
RNA interference cancer treatment? Delivering RNA with tiny sponge-like spheres
Posted: Published on February 28th, 2012
ScienceDaily (Feb. 27, 2012) — For the past decade, scientists have been pursuing cancer treatments based on RNA interference -- a phenomenon that offers a way to shut off malfunctioning genes with short snippets of RNA. However, one huge challenge remains: finding a way to efficiently deliver the RNA. Most of the time, short interfering RNA (siRNA) -- the type used for RNA interference -- is quickly broken down inside the body by enzymes that defend against infection by RNA viruses. "It's been a real struggle to try to design a delivery system that allows us to administer siRNA, especially if you want to target it to a specific part of the body," says Paula Hammond, the David H. Koch Professor in Engineering at MIT. Hammond and her colleagues have now come up with a novel delivery vehicle in which RNA is packed into microspheres so dense that they withstand degradation until they reach their destinations. The new system, described Feb. 26 in the journal Nature Materials, knocks down expression of specific genes as effectively as existing delivery methods, but with a much smaller dose of particles. Such particles could offer a new way to treat not only cancer, but … Continue reading
Comments Off on RNA interference cancer treatment? Delivering RNA with tiny sponge-like spheres
Stem Cell Finding Could Expand Women’s Lifetime Supply of Eggs
Posted: Published on February 28th, 2012
SUNDAY, Feb. 26 (HealthDay News) -- Researchers report that they've isolated stem cells from adult human ovaries that can mature into eggs that may be capable of fertilization. The lab findings, which upend longstanding scientific theory, could potentially lead to new reproductive technologies and possibly extend the years of a woman's fertility. It was long believed that women were born with a lifetime supply of eggs, which was depleted by menopause. But a growing body of research -- including a new paper from Massachusetts General Hospital -- suggests egg production may continue into adulthood. The study is published in the March issue of Nature Medicine. "Fifty years of thinking, in every aspect of experiments, of interpreting the results, and of the clinical management of ovarian function and fertility in women was dictated by one simple belief that turns out to be incorrect," said lead study author Jonathan Tilly, director of the hospital's Vincent Center for Reproductive Biology. "That belief was the egg cell pool endowed at birth is a fixed entity that cannot be renewed." Dr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore-LIJ Health System in Manhasset, N.Y., said the study is "exciting" but emphasized … Continue reading
Posted in Cell Medicine
Comments Off on Stem Cell Finding Could Expand Women’s Lifetime Supply of Eggs
Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs
Posted: Published on February 28th, 2012
SUNDAY, Feb. 26 (HealthDay News) -- Researchers report that they've isolated stem cells from adult human ovaries that can mature into eggs that may be capable of fertilization. The lab findings, which upend longstanding scientific theory, could potentially lead to new reproductive technologies and possibly extend the years of a woman's fertility. It was long believed that women were born with a lifetime supply of eggs, which was depleted by menopause. But a growing body of research -- including a new paper from Massachusetts General Hospital -- suggests egg production may continue into adulthood. The study is published in the March issue of Nature Medicine. "Fifty years of thinking, in every aspect of experiments, of interpreting the results, and of the clinical management of ovarian function and fertility in women was dictated by one simple belief that turns out to be incorrect," said lead study author Jonathan Tilly, director of the hospital's Vincent Center for Reproductive Biology. "That belief was the egg cell pool endowed at birth is a fixed entity that cannot be renewed." Dr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore-LIJ Health System in Manhasset, N.Y., said the study is "exciting" but emphasized … Continue reading
Posted in Cell Medicine
Comments Off on Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs
StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012
Posted: Published on February 28th, 2012
NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is being held in Qatar from February 27 to March 1, 2012. The Company, which is the leader in development of cell-based therapeutics for central nervous system disorders, was specifically invited by the conference's sponsors, the State of Qatar and Amir of Qatar His Highness Sheikh Hamad bin Khalifa Al-Thani, as well as the James A. Baker III Institute for Public Policy of Rice University, and is the only company to be invited. Ann Tsukamoto, Ph.D., StemCells' Executive Vice President, Research and Development, will make a presentation on the clinical translation of human neural stem cells. StemCells was the first company to receive authorization from the US Food and Drug Administration to conduct a clinical trial of purified human neural stem cells, and the Company is currently conducting two clinical trials with a third anticipated to start later this year. Dr. Tsukamoto will also be the moderator of the panel session on neurological disorders, which is scheduled to be held on March 1 from 9:30 a.m. to 11:00 a.m. … Continue reading
Posted in Cell Medicine
Comments Off on StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012
‘Scope for innovation in genetic medicine’
Posted: Published on February 28th, 2012
There is a tremendous opportunity in genetic medicine for innovation and for new players to make significant contributions, because it is still experimental, noted biologist and Nobel Laureate Dr David Baltimore said yesterday. “Today, it is mainly the province of biotechnology companies and universities, not big pharmaceutical companies,” he observed in a keynote presentation at the Qatar International Conference on Stem Cell Science and Policy 2012. There are new genetic tools available – though they are still experimental - to treat diseases which involve adding, subtracting or modifying genes in the cells of the body. “However, they are powerful tools and I am confident they will be an important part of the medicine of the future,” he said. Speaking on ‘The hematopoietic stem cell (HSC) as a target for therapy against cancer and Aids,’ Dr Baltimore explained that HSCs are one of the few cell types routinely used for bone marrow transplant. The HSCs are easily accessible, retroviruses can be used to carry genes into these stem cells, the genes are then expressed in all of cells that derive from the HSC and can correct inherited defects and bring genes that perform therapy under a programme called engineering immunity. “Though … Continue reading
Posted in Cell Medicine
Comments Off on ‘Scope for innovation in genetic medicine’
Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update
Posted: Published on February 28th, 2012
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA - News), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year. 2011 highlights include: Clinical and Regulatory Granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for Tovaxin® for the treatment of patients with Secondary Progressive Multiple Sclerosis (SPMS); Published the results of the Company’s prior Phase IIb TERMS clinical trial of Tovaxin in a leading peer-reviewed publication, Multiple Sclerosis Journal; Executed strategic agreements with the American Red Cross and the Blood Group Alliance, Inc. to streamline blood procurement for future clinical trials; and Met with Health Canada’s Biologics and Genetics Therapies Directorate as part of the process to secure approval for Opexa to conduct a portion of future clinical development in Canada. Operational Optimized the manufacturing process through the implementation of a functionally closed system and single cycle cGMP process; Advanced overall clinical plans for Tovaxin and clearly defined the study protocol for the planned Phase IIb clinical trial in SPMS; Increased employee headcount thereby strengthening our overall cell therapy expertise in preparation … Continue reading
Posted in Cell Therapy
Comments Off on Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update
Alonso Krangle LLP Conducting Yaz Lawsuit Investigation Due to Alleged Yaz Side Effects of Blood Clots, Heart Attacks …
Posted: Published on February 28th, 2012
Alonso Krangle LLP conducting an investigation into Yaz lawsuits due to side effects allegedly caused by Yaz birth control pills, including blood clots, deep vein thrombosis, pulmonary embolism, heart attack, stroke and sudden death. Melville, NY (PRWEB) February 28, 2012 The founding partners of Alonso Krangle LLP, Attorneys Andres Alonso and David Krangle are focused on fighting for the rights of victims due to drug side effects, continue to investigate harmful Yaz side effects allegedly caused by Yaz birth control pills. Alonso Krangle LLP is currently offering free Yaz lawsuit evaluations to any woman, or their family, who may have sustained serious injuries or life-threatening side effects because of Yaz including: Blood clots Heart attack Stroke Sudden death Pulmonary Embolism Deep vein thrombosis If you have been injured and need help regarding a potential Yaz lawsuit claim with one of the compassionate and experienced defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com. Yaz Lawsuits and Yasmin Lawsuits Update Attorney Andres Alonso of Alonso Krangle LLP is presently serving as a member of the Plaintiffs’ Steering Committee in regards to the present litigation of more than 10,000 personal injury Yaz lawsuits and … Continue reading
Posted in Drug Side Effects
Comments Off on Alonso Krangle LLP Conducting Yaz Lawsuit Investigation Due to Alleged Yaz Side Effects of Blood Clots, Heart Attacks …
Takeda’s TAK-875 Fights Diabetes as Well as Older Drug in Study
Posted: Published on February 28th, 2012
February 27, 2012, 10:27 PM EST By Simeon Bennett Feb. 27 (Bloomberg) -- Takeda Pharmaceutical Co.’s experimental diabetes drug lowered blood sugar as much as an older generic medicine with fewer side effects, a company- sponsored study found. In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who got glimepiride, the older drug, according to findings published online by The Lancet medical journal today. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego. Takeda is testing TAK-875 in the third and final stage of patient studies usually required for regulatory approval. The Osaka, Japan-based company seeks products to replace sales of Actos, the world’s best-selling diabetes treatment, that will be lost when the therapy’s patent protection ends this year. About 90 percent of the 285 million people worldwide with diabetes have Type 2, the form that TAK-875 is designed to fight. The pill belongs to a new class of treatments called GPR40 agonists, which activate a receptor that stimulates and regulates insulin production. New treatments … Continue reading
Posted in Drug Side Effects
Comments Off on Takeda’s TAK-875 Fights Diabetes as Well as Older Drug in Study
2 Health Care Stocks Hitting 52-Week Highs: MHS, ISRG
Posted: Published on February 28th, 2012
NEW YORK (TheStreet) - Medco Health Solutions(MHS) and Intuitive Surgical(ISRG) both hit 52-week highs on Monday. Both stocks are rated buy at TheStreet Ratings. Medco Health Solutions The pharmacy benefit manager got a boost as expectations grew that it would be able to complete its planned merger with Express Scripts(ESRX), according to The Wall Street Journal, which cited a report by anti-trust research firm MLex as saying it expects the combination to win anti-trust approval. The company also reported its above-consensus fourth-quarter earnings last week. "New business trends were more positive than we expected, as the company has won $2.6 billion in gross new business in 2012," William Blair analysts wrote in a Feb. 21 report. "While net new wins are still negative for the year (given previously disclosed losses), there have been no new significant losses since the third-quarter call, suggesting net new business wins over the past three months were also about $1 billion." Shares of Medco Health Solutions hit a 52-week high of $68.40. The stock's 52-week low of $44.60 was set on Oct. 4. Medco Health Solutions has an estimated price-to-earnings ratio for next year of 14.06; the average for health care providers is 18.75. For … Continue reading
Posted in Wholesale Pharmacy
Comments Off on 2 Health Care Stocks Hitting 52-Week Highs: MHS, ISRG